keyword
MENU ▼
Read by QxMD icon Read
search

Intravesical therapy

keyword
https://www.readbyqxmd.com/read/29152556/bladder-sparing-therapy-for-bcg-failures-i-intravesical-immunotherapy
#1
Edward M Messing
No abstract text is available yet for this article.
October 27, 2017: Bladder Cancer
https://www.readbyqxmd.com/read/29152553/oncological-outcomes-of-sequential-intravesical-gemcitabine-and-docetaxel-in-patients-with-non-muscle-invasive-bladder-cancer
#2
Niv Milbar, Max Kates, Meera R Chappidi, Filippo Pederzoli, Takahiro Yoshida, Alexander Sankin, Phillip M Pierorazio, Mark P Schoenberg, Trinity J Bivalacqua
Background: Bacillus Calmette-Guérin (BCG) unresponsive/relapsing patients with non-muscle invasive bladder cancer (NMIBC) who prefer bladder preservation over radical cystectomy (RC) or those who do not qualify for surgery may be offered intravesical therapies. Gemcitabine (GEM) combined with Docetaxel (DOCE) has been offered at Johns Hopkins Hospital (JHH). Objective: To evaluate experience with GEM/DOCE, to confirm safety of the regimen, to identify populations that may benefit most, and to consider the appropriate endpoints for judging efficacy of second line therapies...
October 27, 2017: Bladder Cancer
https://www.readbyqxmd.com/read/29145329/new-onset-of-myasthenia-gravis-after-intravesical-bacillus-calmette-guerin-a-case-report-and-literature-review
#3
Tsubasa Takizawa, Marenori Kojima, Shigeaki Suzuki, Takashi Osada, Satoshi Kitagawa, Jin Nakahara, Shinichi Takahashi, Norihiro Suzuki
RATIONALE: Recently, drug-related myasthenia gravis (MG) has received attention, because the number of reported cases involving MG associated with immune checkpoint inhibitors, a new immunotherapy, is increasing. We present a case involving the new onset of MG, in which the symptoms started shortly after intravesical Bacillus Calmette-Guerin (BCG) for bladder cancer. PATIENT CONCERNS: A 69-year-old male with bladder cancer developed ptosis and diplopia 4 days after the completion of a treatment regimen with intravesical BCG weekly for 6 weeks...
November 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29135135/-ultrasound-indicators-of-the-prostate-urinary-bladder-and-uroflowmetry-parameters-in-the-diagnosis-of-infravesical-obstruction-in-men-with-benign-prostatic-hyperplasia
#4
G G Krivoborodov, N S Efremov, A D Bolotov
RELEVANCE: Benign prostatic hyperplasia (BPH) is one of the most common urologic diseases of males. In patients who failed drug therapy of lower urinary tract symptoms (LUTS) caused by BPH, the most important indication for surgery is the presence of infravesical obstruction (IVO). IVO is detected by pressure-flow studies and is characterized by high detrusor pressure with decreased urinary flow rate. The invasiveness and high cost of this investigation has stimulated a search for non-invasive techniques that could reliably characterize the presence of IVO secondary to BPH...
October 2017: Urologii︠a︡
https://www.readbyqxmd.com/read/29118530/prognostic-impact-of-bacillus-calmette-gu%C3%A3-rin-interruption-at-the-time-of-induction-and-consolidation
#5
M Mofarej Alhogbani, J Aude Picard, M Hakim Fassi-Fehri, J Lionel Badet, C Marc Colombel
Context: Intravesical Bacillus Calmette-Guérin (BCG) is a cause of bladder and systemic toxicity that is difficult to prevent and is responsible for treatment drop out in bladder cancer patients. More recently, BCG shortage has become the main cause of incomplete treatment. Aims: The aim of this study was to examine the impact on long-term prognosis of bladder cancer patients following discontinuation of BCG instillations. Settings and Design: In this retrospective study, data were examined from 333 consecutive nonmuscle invasive bladder cancer patients treated from 2005 to 2015 by transurethral resection (TUR) and had undergone adjuvant BCG therapy after TUR...
October 2017: Urology Annals
https://www.readbyqxmd.com/read/29117930/psychometric-evaluation-of-a-patient-reported-symptom-index-for-nonmuscle-invasive-bladder-cancer-field-testing-protocol
#6
Claudia Rutherford, Madeleine T King, David P Smith, Daniel Sj Costa, Margaret-Ann Tait, Manish I Patel
BACKGROUND: Nonmuscle invasive bladder cancer (NMIBC) is a chronic condition requiring intensive follow-up, repeated endoscopic examinations, tumor resections, and intravesical treatments that can occur every 3 months for life. In this clinical context, patient-reported outcomes (PROs) are a critical concern for patients and their managing clinicians. PROs have enormous potential to be integral to treatment assessment and recommendations for NMIBC; however, current PRO measures are inadequate for NMIBC because they lack key NMIBC-specific symptoms and side effects associated with contemporary treatments...
November 8, 2017: JMIR Research Protocols
https://www.readbyqxmd.com/read/29113841/immunotherapy-with-checkpoint-blockade-in-the-treatment-of-urothelial-carcinoma
#7
REVIEW
Arlene O Siefker-Radtke, Andrea B Apolo, Trinity J Bivalacqua, Philippe E Spiess, Peter C Black
PURPOSE: Although immunotherapy has a long history in the treatment of urothelial carcinoma, its use was limited to intravesical therapy for non-muscle-invasive disease. The development of immune checkpoint blockers for systemic delivery has expanded the application of immunotherapy to advanced metastatic urothelial cancers. MATERIALS AND METHODS: The PubMed database was searched for publications regarding immune checkpoint blockers for the treatment of patients with urothelial carcinoma...
November 4, 2017: Journal of Urology
https://www.readbyqxmd.com/read/29103257/-fever-hepatic-dysfunction-and-interstitial-pneumonia-caused-by-intravesical-bacillus-calmette-guerin-bcg-instillation-after-urethral-bougie-a-case-report
#8
Satoshi Nitta, Shotaro Sakka, Tsuyoshi Endo, Manabu Komine, Masakazu Tsutsumi, Hiroyuki Nishiyama
A 60-year-old man had a past history of urothelial carcinoma of the left renal pelvis treated with laparoscopic left total nephroureterectomy in October 2004. He underwent transurethral resection of the bladder tumor (TUR-Bt) twice for recurrence of urothelial carcinoma in the bladder in April 2014 and February 2015, and subsequently received intravesical Bacillus Calmette-Guerin (BCG) instillation at weekly intervalsfor prevention of recurrence. In November 2016, a year and a half after BCG induction, he received BCG therapy after urethral bougie to dilate the urethral stricture...
October 2017: Hinyokika Kiyo. Acta Urologica Japonica
https://www.readbyqxmd.com/read/29101762/availability-and-patterns-of-intravesical-bcg-instillations
#9
S Awomir Poletajew, Aleksandra Majek, Piotr Magusiak, Katarzyna Ledzikowska, Bartosz Dybowski, Piotr Radziszewski
PURPOSE: Intravesical BCG instillations improve recurrence free survival in patients with non-muscle-invasive bladder cancer (NMIBC). METHODS: This is a national survey study, covering 223 urological centres, aimed at reliable identification of BCG availability and implemented treatment patterns. RESULTS: Response rate was 93.7%. BCG was used in 56.5% of urological departments. Another 22.7% referred patients to other hospitals for instillations, while 20...
November 4, 2017: Urology Journal
https://www.readbyqxmd.com/read/29093394/mycobacterium-bovis-induced-aneurysm-after-intravesical-bacillus-calmette-gu%C3%A3-rin-therapy-a-case-study-and-literature-review
#10
Yoshitsugu Higashi, Shigeki Nakamura, Kento Kidani, Kaoru Matumoto, Koyomi Kawago, Junko Isobe, Junichi Kanatani, Yukio Kawagishi, Ippei Sakamaki, Yoshihiro Yamamoto
Mycobacterium bovis infection after intravesical Bacillus Calmette-Guérin (BCG) therapy is rare. A 65-year-old Japanese man with history of bladder cancer and intravesical BCG therapy, presented with low-grade fever. An aneurysm with perianeurysmal fluid was suspected and endovascular aortic repair was performed. After 160 days, he developed blood-streaked sputum and computed tomography images revealed that the perianeurysmal fluid area was increasing in size. A multiplex polymerase chain reaction using sputum identified M...
November 1, 2017: Internal Medicine
https://www.readbyqxmd.com/read/29081034/primary-high-grade-non-muscle-invasive-bladder-cancer-high-nf%C3%AE%C2%BAb-expression-in-tumor-specimens-distinguishes-patients-who-are-at-risk-for-disease-progression
#11
Lampros Mitrakas, Stavros Gravas, Christos Papandreou, Georgios Koukoulis, Foteini Karasavvidou, Georgios Dimakopoulos, Karl Weingärtner, Anastasios Karatzas, Ioannis Zachos, Vasilios Tzortzis
To investigate the potential prognostic role of NFκB expression in primary high-grade non-muscle-invasive bladder cancer. Patients with primary high-grade non-muscle-invasive bladder cancer who received induction and maintenance BCG therapy were retrospectively included. Recurrence and progression were histologically proven. Intensity and extent of immunochemistry were assessed. The final evaluation of the NFκB staining was done by combining intensity and extent as ΄΄product΄΄ and expressing it as ΄΄low NFκΒ expression΄΄ or ΄΄high NFκB expression΄΄...
October 28, 2017: Pathology Oncology Research: POR
https://www.readbyqxmd.com/read/29055653/predicting-response-to-intravesical-bacillus-calmette-gu%C3%A3-rin-immunotherapy-are-we-there-yet-a-systematic-review
#12
REVIEW
Ashish M Kamat, Roger Li, Michael A O'Donnell, Peter C Black, Morgan Roupret, James W Catto, Eva Comperat, Molly A Ingersoll, Wim P Witjes, David J McConkey, J Alfred Witjes
CONTEXT: Bacillus Calmette-Guérin (BCG) is currently the most effective intravesical therapy for nonmuscle invasive bladder cancer, reducing not only recurrence rates but also preventing progression and reducing deaths. However, response rates to BCG vary widely and are dependent on a multitude of factors. OBJECTIVE: To review existing data on clinical, pathologic, immune, and molecular markers that allow prediction of BCG response. EVIDENCE ACQUISITION: PubMed and MEDLINE search of English language literature was conducted from its inception to July 2017 using appropriate search terms...
October 18, 2017: European Urology
https://www.readbyqxmd.com/read/29049231/dose-duration-and-strain-of-bacillus-calmette-guerin-in-the-treatment-of-nonmuscle-invasive-bladder-cancer-meta-analysis-of-randomized-clinical-trials
#13
Yongjun Quan, Chang Wook Jeong, Cheol Kwak, Hyeon Hoe Kim, Hyung Suk Kim, Ja Hyeon Ku
BACKGROUND: Intravesical bacillus Calmette-Guerin (BCG) instillation is widely used as an adjuvant therapy after transurethral resection of bladder tumor (TURBT) in patients with intermediate- and high-risk nonmuscle invasive bladder cancer (NMIBC). However, the effective dose, duration, and strain of BCG have not yet been clearly determined. We aimed to elucidate the relationship between dose, duration, and strain of BCG and clinical outcomes in NMIBC patients treated with TURBT. METHODS: We conducted a literature search in Embase, Scopus, and PubMed databases for all relevant articles published up to October 2016 in accordance with the Preferred Reporting Items for Systematic Review and Meta-analysis guidelines...
October 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29046985/new-devices-and-technologies-for-the-management-of-overactive-bladder
#14
REVIEW
Juan M Guzman-Negron, Howard B Goldman
PURPOSE OF REVIEW: Overactive bladder (OAB) affects millions of people in the USA and has a significant impact on their quality of life. Despite having a number of safe and effective ways of managing refractory OAB patients, there are many promising new technologies actively being studied and developed for the treatment of this population. This review examines current new devices and technologies under study for the treatment of OAB. RECENT FINDINGS: Modifications to already established therapies such as sacral nerve stimulation (SNS) or tibial nerve stimulation (TNS) are currently being studied for refractory OAB...
October 18, 2017: Current Urology Reports
https://www.readbyqxmd.com/read/29034722/the-efficacy-of-apaziquone-in-the-treatment-of-bladder-cancer
#15
Francisco Caramés Masana, Theo M de Reijke
Bladder cancer is nowadays a common tumor. Non-muscle invasive bladder cancer (NMIBC) has still chances of recurrence and progression in spite of surgery and adjuvant treatments. New therapies are being developed to reduce these percentages with less adverse effects - Apaziquone (EO9) is an example. Areas covered: A literature search has been performed using Pubmed, UpToDate and Google verified information (mainly from Food and Drug Administration and Spectrum Pharmaceutics websites). We have included data from the most representative clinical trials and reviews published...
October 20, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29034173/mycobacteria-bovis-osteomyelitis-following-intravesical-bcg-for-bladder-cancer
#16
Karan Seegobin, Satish Maharaj, Cherisse Baldeo, Carmen Isache, Bharatsinh Gharia, Lara Zuberi
Mycobacteria Bovis osteomyelitis is a rare adverse effect after Bacillus Calmette-Guerin (BCG) intravesical therapy. A 62-year-old male presented with acute spinal cord compression three months after completing his second course of therapy for bladder cancer. The first course with intravesical BCG was complicated with an episode of hematuria. He reported intermittent subjective fever for 3 weeks thereafter which resolved with Tylenol. Interferon-α2 B was added to the second cycle of intravesical BCG with the indication here being residual tumor, and was tolerated well...
2017: IDCases
https://www.readbyqxmd.com/read/29030178/a-lectin-mediated-delivery-system-for-the-intravesical-treatment-of-bladder-diseases-using-poly-l-glutamic-acid-as-polymeric-backbone
#17
Christina Apfelthaler, Patrick Gassenbauer, Sandra Weisse, Franz Gabor, Michael Wirth
In this study, we present a targeted drug delivery system to improve intravesical therapy of bladder diseases. The drug delivery system consists of wheat germ agglutinin (WGA) to facilitate specific interaction with the surface of bladder cells and α-poly-(L)-glutamic acid (PGA) as polymeric backbone to increase the number of drug molecules per targeting moiety. Additionally, fluorescein cadaverine was coupled to PGA to visualise and track the delivery system. Using 5637 single cells and cell monolayers, the optimised F-PGA-WGA delivery system, with an approximate molecular weight of 670kDa, could convince with its promising cytoadhesive as well as cytoinvasive potential...
October 13, 2017: European Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/29028078/a-natural-pharma-standard-supplement-formulation-to-control-treatment-related-toxicity-and-oxidative-stress-in-genitourinary-cancer-a-preliminary-study
#18
A Ledda, G Belcaro, M Dugall, R Luzzi, M Hosoi, B Feragalli, R Cotellese, V Cosentino, M Cosentino, R Eggenhoffner, M Pellizzato, A Fratter, L Giacomelli
OBJECTIVE: Oncological treatments are associated with toxicities that may decrease compliance to treatment in most genitourinary cancer patients. Supplementation with pharmaceutical-standardized supplement may be a supplementary method to control the side effects after chemo- and radiotherapy and the increased oxidative stress associated to treatments. This registry study evaluated a natural combination of supplements containing curcumin, cordyceps, and astaxanthin (Oncotris™) used as supplementary management in genitourinary cancer patients who had undergone oncological therapy...
September 2017: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/29021649/follow-up-urodynamics-in-patients-with-neurogenic-bladder
#19
REVIEW
Sanjay Sinha
INTRODUCTION: Neurogenic bladder patients are at long-term risk of secondary upper urinary tract damage. Symptoms are unreliable and follow-up urodynamics is the only method of ascertaining safety of bladder pressures. This review examines the recommendations, shortcomings and utilization of existing guidelines. The evidence with regard to follow-up urodynamics in different settings relevant to neurogenic bladder is evaluated and an algorithm is proposed. METHODS: A pubmed search was conducted for studies on follow-up urodynamics in patients with neurogenic bladder...
October 2017: Indian Journal of Urology: IJU: Journal of the Urological Society of India
https://www.readbyqxmd.com/read/28994883/long-term-outcome-of-intravesical-bacillus-calmette-gu%C3%A3-rin-therapy-with-maintenance-for-urinary-bladder-carcinoma-in-situ-about-47-cases
#20
Sataa Sallami, Hassen Khouni, Mahmoud Ben Atta, Sana Abou El Makarim, Mohamed Bechir Zouari, Sami Ben Rhouma
INTRODUCTION: Data concerning the efficacy of intravesical Bacillus Calmette-Guerin (BCG) on carcinoma in situ (CIS) of the bladder are limited. OBJECTIVES: We analyzed long-term outcomes of instillation therapy with BCG to treat bladder CIS, evaluated its effectiveness and safety and searched for prognostic factors that could predict disease recurrence and progression. METHODS: Between March 1994 and December 2010, 47 patients (male: 40; female: 7) with median age of 59,5 years (range 40-76 years), diagnosed with bladder CIS underwent weekly BCG instillations (75 mg of Pasteur strain) for six weeks followed by 6 monthly instillations...
December 2016: La Tunisie Médicale
keyword
keyword
21306
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"